Antiretroviral Therapy, Highly Active
"Antiretroviral Therapy, Highly Active" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drug regimens, for patients with HIV INFECTIONS, that aggressively suppress HIV replication. The regimens usually involve administration of three or more different drugs including a protease inhibitor.
| Descriptor ID |
D023241
|
| MeSH Number(s) |
E02.319.310.075
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antiretroviral Therapy, Highly Active".
Below are MeSH descriptors whose meaning is more specific than "Antiretroviral Therapy, Highly Active".
This graph shows the total number of publications written about "Antiretroviral Therapy, Highly Active" by people in this website by year, and whether "Antiretroviral Therapy, Highly Active" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 1 | 2 |
| 2002 | 3 | 6 | 9 |
| 2003 | 6 | 6 | 12 |
| 2004 | 4 | 8 | 12 |
| 2005 | 8 | 5 | 13 |
| 2006 | 4 | 6 | 10 |
| 2007 | 4 | 8 | 12 |
| 2008 | 2 | 3 | 5 |
| 2009 | 5 | 5 | 10 |
| 2010 | 8 | 10 | 18 |
| 2011 | 4 | 11 | 15 |
| 2012 | 3 | 4 | 7 |
| 2013 | 6 | 5 | 11 |
| 2014 | 3 | 3 | 6 |
| 2015 | 9 | 3 | 12 |
| 2016 | 3 | 7 | 10 |
| 2017 | 0 | 3 | 3 |
| 2018 | 3 | 0 | 3 |
| 2019 | 1 | 2 | 3 |
| 2020 | 1 | 3 | 4 |
| 2021 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antiretroviral Therapy, Highly Active" by people in Profiles.
-
Longitudinal Effects of Combination Antiretroviral Therapy on Cognition and Neuroimaging Biomarkers in Treatment-Naive People With HIV. Neurology. 2022 09 06; 99(10):e1045-e1055.
-
Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. Nat Med. 2021 10; 27(10):1718-1724.
-
Brief Report: Are Serious Falls Associated With Subsequent Fragility Fractures Among Veterans Living With HIV? J Acquir Immune Defic Syndr. 2021 10 01; 88(2):192-196.
-
The effect of non-AIDS-defining cancers on people living with HIV. Lancet Oncol. 2021 06; 22(6):e240-e253.
-
Etiology and pathophysiology of heart failure in people with HIV. Heart Fail Rev. 2021 05; 26(3):497-505.
-
Vitamin D Assessment Over 48 Weeks in Treatment-Naive HIV Individuals Starting Lopinavir/Ritonavir Monotherapy. Curr HIV Res. 2021; 19(1):61-72.
-
Infection or drug toxicity? Acute ataxia and encephalopathy after uncomplicated falciparum malaria and efavirenz dose adjustment. Malawi Med J. 2020 12; 32(4):229-231.
-
Sexual Behavior and Sexually Transmitted Infection Outcomes Among Men Who Have Sex With Men and Transgender Women Participating in a Study of the Timing of Antiretroviral Therapy in Lima, Peru. Sex Transm Dis. 2020 12; 47(12):825-831.
-
Impact of previous HIV resistance and virologic failures on virologic outcome following a switch to dolutegravir with 2 NRTIs among people living with HIV. Medicine (Baltimore). 2020 Nov 20; 99(47):e23335.
-
Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study. Lancet HIV. 2020 09; 7(9):e602-e610.